RAFAEL HOLDINGS, INC. Other Restructuring Costs
RAFAEL HOLDINGS, INC. (RFL) reported Other Restructuring Costs of $1.20 million for the 6-month period ending 2024-01-31, per its 10-Q filed 2024-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherRestructuringCosts · last filed 2024-03-14
- RAFAEL HOLDINGS, INC. other restructuring costs for the quarter ending 2024-01-31 was $0.00.
- RAFAEL HOLDINGS, INC. other restructuring costs for the quarter ending 2023-10-31 was $1.20M.
- RAFAEL HOLDINGS, INC. other restructuring costs for fiscal 2023 was $1.20M.
| Period end | Other Restructuring Costs 3 month | Other Restructuring Costs 6 month | Other Restructuring Costs 12 month |
|---|---|---|---|
| 2024-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-03-14 | $1.20M 10-Q · filed 2024-03-14 | |
| 2023-10-31 | $1.20M 10-Q · filed 2023-12-14 | ||
| 2023-07-31 | $1.20M 10-K · filed 2023-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |